The therapeutic landscape of melanoma has shifted dramatically, with dual checkpoint blockade emerging as a cornerstone of care. Nivolumab plus relatlimab has demonstrated superior progression-free survival and a favorable safety profile compared to traditional CTLA-4/PD-1 combinations. 1 Its NCCN Category 1 designation and ESMO endorsement highlight its role as a preferred first-line regimen across diverse patient populations. With reduced immune-related toxicity and durable responses, nivolumab + relatlimab is shaping a new era in melanoma management. 2,3 Together, evidence and guidelines converge to recommend dual checkpoint inhibitor (nivolumab + relatlimab) as a pivotal therapy in advanced melanoma care.
##References## Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022;386(1):24-34. Swetter SM,…
